Novo Nordisk A/S
NYSE:NVO · New York Stock Exchange
-$0.48 today
Vol 7.98M · Avg 16.05M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $21.1B |
| Short-term Investments | $499.0M |
| Receivables | $100.3B |
| Inventory | $51.4B |
| Other Current | $4.1B |
| Total Current Assets | $177.3B |
| PP&E (Net) | $220.0B |
| Goodwill | $19.9B |
| Intangible Assets | $110.0B |
| Long-term Investments | $2.2B |
| Tax Assets | $23.8B |
| Other Non-current | $6.0B |
| Total Non-current Assets | $381.9B |
| Total Assets | $559.2B |
Analysis
Selected assets total $559.2B for Latest. The largest visible component is PP&E (Net) at $220.0B, about 39.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.5B +69.0% | $15.7B +8.8% | $14.4B +13.7% | $12.7B +18.0% | $10.7B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $498.0M -95.3% | $10.7B -32.7% | $15.8B +45.0% | $10.9B +61.4% | $6.8B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $75.7B -13.4% | $87.4B +16.1% | $75.3B +30.9% | $57.5B +22.9% | $46.8B | $533.8M | $399.4M | -$1.7B |
| Inventory | $49.6B +21.5% | $40.8B +28.4% | $31.8B +30.4% | $24.4B +24.3% | $19.6B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $20.2B +218.9% | $6.3B +169.9% | $2.3B -75.8% | $9.7B +472.3% | $1.7B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $172.5B +7.2% | $160.9B +15.2% | $139.6B +29.1% | $108.2B +26.4% | $85.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $208.4B +28.2% | $162.5B +78.6% | $91.0B +36.4% | $66.7B +20.4% | $55.4B | $1.2B | $1.5B | $687.8M |
| Goodwill | $19.8B -1.1% | $20.1B +349.5% | $4.5B -12.3% | $5.1B +17.2% | $4.3B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $110.2B +21.1% | $91.0B +62.7% | $55.9B +20.8% | $46.3B +19.3% | $38.8B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.5B -6.4% | $2.7B +61.0% | $1.7B +23.8% | $1.3B -6.8% | $1.4B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $23.6B -4.0% | $24.6B +20.8% | $20.4B +51.8% | $13.4B +54.8% | $8.7B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $5.9B +46.0% | $4.0B +180.8% | $1.4B +594.2% | $206.0M -22.8% | $267.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $370.4B +21.5% | $304.9B +74.4% | $174.8B +31.4% | $133.1B +22.2% | $108.9B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $542.9B +16.6% | $465.8B +48.1% | $314.5B +30.4% | $241.3B +24.0% | $194.5B | $13.3B | $11.9B | $10.6B |
| Account Payables | $19.8B -31.5% | $28.8B +12.7% | $25.6B +64.3% | $15.6B +75.7% | $8.9B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $12.0B +2.1% | $11.8B +122.0% | $5.3B +1005.0% | $480.0M -96.3% | $12.9B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $9.7B +36.5% | $7.1B +0.4% | $7.1B +93.8% | $3.7B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $175.5B +5.8% | $165.9B +334.8% | $38.1B -60.6% | $96.8B +32.0% | $73.3B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $215.7B -0.9% | $217.5B +28.2% | $169.7B +40.3% | $120.9B +21.5% | $99.5B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $110.4B +31.0% | $84.2B +427.3% | $16.0B -23.1% | $20.8B +115.2% | $9.7B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $6.6B +21.8% | $5.4B -46.6% | $10.2B +43.9% | $7.1B +34.0% | $5.3B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $7.6B -21.1% | $9.7B +27.7% | $7.6B +39.0% | $5.5B -9.3% | $6.0B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $133.2B +27.1% | $104.8B +173.8% | $38.3B +3.9% | $36.8B +51.9% | $24.2B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $348.9B +8.2% | $322.3B +55.0% | $207.9B +31.8% | $157.8B +27.5% | $123.8B | $14.7B | $3.7B | $9.6B |
| Common Stock | $446.0M +0.0% | $446.0M -1.1% | $451.0M -1.1% | $456.0M -1.3% | $462.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $195.3B +35.2% | $144.4B +37.8% | $104.8B +30.1% | $80.6B +11.9% | $72.0B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.7B -20.6% | -$1.4B -210.2% | $1.3B -47.9% | $2.4B +242.9% | -$1.7B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $194.0B +35.2% | $143.5B +34.7% | $106.6B +27.6% | $83.5B +18.0% | $70.7B | $9.1B | $7.7B | $3.3B |
| Total Debt | $131.0B +27.4% | $102.8B +280.6% | $27.0B +4.7% | $25.8B -3.2% | $26.6B | $724.2M | $410.6M | $399.4M |
| Net Debt | $104.5B +19.9% | $87.1B +590.8% | $12.6B -3.9% | $13.1B -17.5% | $15.9B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$281.73B
Novartis AG
NYSE:NVS
$281.18B
AstraZeneca PLC
NYSE:AZN
$271.11B
Amgen Inc.
NASDAQ:AMGN
$180.68B
Thermo Fisher Scientific Inc.
NYSE:TMO
$173.24B
Abbott Laboratories
NYSE:ABT
$153.30B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.54B
Pfizer Inc.
NYSE:PFE
$143.68B
GSK plc
NYSE:GSK
$101.90B
Sanofi
NASDAQ:SNY
$101.56B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NVO have?
Novo Nordisk A/S (NVO) reported $26.46B in cash and equivalents in fiscal 2025.
How much debt does NVO carry?
Novo Nordisk A/S (NVO) reported $130.96B of total debt, with net debt of $104.49B.
Explore More
Continue the stock analysis
Jump to another research area for this company.